ASGO The 4th International Workshop on Gynecologic Oncology

Program & Abstracts

Date November 12 (Sat), 2016
Venue Sendai International Center, Japan
President Nobuo YAEGASHI, M.D., Ph.D
ASGO The 4th International Workshop on Gynecologic Oncology
Meeting Information

Date and Venue
Date: November 12 (Sat), 2016
Venue: Meeting Room 4, Exhibition Building, Sendai International Center
        Aobayama, Aoba-ku, Sendai 980-0856, Japan
        Tel: +81-22-265-2211
        URL: http://www.aobayama.jp/english/

Contact
Organizing Secretariat
ASGO The 4th International Workshop on Gynecologic Oncology/
39th Annual Meeting of the Japan Society of Gynecological and Obstetrical Surgery
c/o MA Convention Consulting, Inc.
Kojimachi Parkside Building 402, 4-7 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan
TEL: 81-(0)3-5275-1191/FAX: 81-(0)3-5275-1192
E-mail: info@macc.jp

Official Website

Registration
On-site Registration  5,000 JPY (Cash/Credit card)
(For participation of ASGO The 4th International Workshop on Gynecologic Oncology only.)
Registration includes admission to all the scientific program of ASGO The 4th International Workshop on Gynecologic Oncology, exhibition and meeting publications.
All registrants are invited to Evening Party which takes place on November 12 (Sat).

Registration Desk:
Exhibition Hall 1, Exhibition Building, Sendai International Center

Opening Hours
7:00-15:00, November 12 (Sat)

Lunch
Lunch boxes will be provided free of charge, at the entrance of Lunchtime Seminar's room on a first-come, first-served basis.

Social Event
Evening Party
Date and Time: 15:25-16:25, November 12 (Sat)
Venue: Exhibition Hall 1, Exhibition Hall, Sendai International Center
Dress Code: Casual (Snacks and drinks will be offered.)
Instructions Regarding Scientific Program

Instructions for Speakers/Reviewers

Time allotted for one session is 50 minutes, whose time constitution is as follows:
1. 25-minute presentation by speaker
2. 10-minute peer review by reviewer
3. 15-minute discussion

All the sessions are guided by chairpersons.

Official Language
All the sessions at ASGO The 4th Workshop on Gynecologic Oncology shall be offered in English.

PC Preview
All the speakers/reviewers are requested to bring their presentation data on USB Flash Drive, CD-R or their own computer to PC Preview Desk and to upload their presentation data at least 30-min before their session.

PC Preview Desk : Exhibition Hall 1, Exhibition Hall, Sendai International Center

Opening Hours
7:00, November 12 (Sat)

[Notes]
2) Recommended typefaces are Century, Century Gothic, Arial, and Times New Roman. Please avoid special characters.
3) Please include the presentation number and presenter’s name in the file name.
4) If you create your presentation using a Macintosh and/or moving images, please bring your own computer.
5) If you use your own computer, please bring your power adaptor.
6) Presenter Tool displaying your manuscript on PC monitor at the podium is not available.

Instructions for Chairpersons
All the chairpersons are requested to be seated at next chairperson’s seat placed in the front row of the room 30 minutes before their session starts.

Instructions for Japanese participants/日本人参加者の皆さまへ

日本婦人科腫瘍学会 単位付与について
ASGO The 4th International Workshop on Gynecologic Oncologyの参加者には、婦人科腫瘍専門医更新のためのポイント（1ポイント）が付与されます。
更新時、参加章のコピーを日本婦人科腫瘍学会までご送付ください。
General Information About Japan

Passport & Visa
To visit Japan, visitors must have a valid passport. A visa is required for citizens of countries that do not have visa exemption agreements with Japan. Please contact your nearest Japanese Embassy or Consulate for visa requirements.

Duty Free Imports
Personal effects and professional equipment can be brought into Japan duty free as long as the items and quantities are deemed reasonable by the customs officer. Visitors can also bring in 400 cigarettes, 500g of tobacco or 100 cigars; 3 bottles of alcoholic beverages; 2oz of perfume; and gifts and souvenirs with a total market price of less than 200,000 yen or equivalent.
There is no allowance for tobacco or alcoholic beverages for persons aged 19 years or younger. Firearms and other types of weapons and narcotics are strictly prohibited.

Insurance
The organizer accepts no responsibility for accidents that might occur. Delegates are encouraged to purchase travel insurance before leaving their home countries. Insurance plans typically cover accidental loss of belongings, medical costs in case of injury or illness, and other risks of international travel.

Climate
The temperature in Sendai in November could range between 5°C-14°C.

Currency Exchange
Only Japanese yen (¥) is acceptable at regular stores and restaurants. Certain foreign currencies may be accepted at a limited number of hotels, restaurants and souvenir shops. You can buy yen at foreign exchange banks on presentation of your passport.

Traveler’s Checks & Credit Cards
Traveler’s checks are accepted only by leading banks and major hotels in principal cities, and the use of traveler’s checks in Japan is not as popular as in some other countries. VISA, MasterCard, Diners Club, and American Express are widely accepted at hotels, department stores, shops, restaurants and nightclubs.

Tipping
In Japan, tips are not necessary anywhere, even at hotels and restaurants.

Electricity
Electric current is uniformly 100 volts AC throughout Japan. However, electricity is provided at either 50 or 60 cycles, depending on location: 50 cycles in eastern Japan (including Tokyo); and 60 cycles in western Japan. Leading hotels in major cities often provide two types of electrical outlets (100 volts and 220 volts), but their sockets usually accept only two pronged plugs.

Shopping
Shops and other sales outlets in Japan are generally open on Saturdays, Sundays and national holidays as well as weekdays from 10:00 to 19:00. Department stores, however, are closed on one weekday a week differing by store. Certain specialty shops may not open on Sundays and national holidays.
Program

Room 3 (Conference Room 4)

Opening Remarks

November 12 (Sat)  9:50～10:00
Room 3  (Conference Room 4)

Ikuo Konishi
(National Hospital Organization Kyoto Medical Center, Japan)
Soon-Beom Kang
(Konkuk University Hospital, Korea)

Session IA

November 12 (Sat)  10:00～11:00
Room 3  (Conference Room 4)

Cervical Cancer, Early Stage

Chairpersons: Yuen Sheung Hextan Ngan (The University of Hong Kong, China)
Hiroyuki Yoshikawa (Ibaraki Prefectural Central Hospital, Japan)
Tadao Takano
(Tohoku University, Japan)

SIA  Peer Review

Nonrandomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2cm or less FIGO stage IB1 uterine cervical cancer (JCOG1101)
Takahide Arimoto¹, Takahiro Kasamatsu²
(Department of Obstetrics and Gynecology, The University of Tokyo, Japan¹, Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokutoh Hospital, Japan²)

Session IB

November 12 (Sat)  11:00～12:00
Room 3  (Conference Room 4)

Cervical Cancer, Late Stage

Chairpersons: Kimio Ushijima (Krume University Hospital, Japan)
Daisuke Aoki (Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)

SIB  Peer Review

Chunling Chen
(Obstetrics and Gynecology Beijing Jadecare Medical Hospital, Beijing, China)
Conventional Versus Dose-Dense Paclitaxel in the Combination with Carboplatin in Metastatic or Recurrent Cervical Cancer (JCOG1311)

Ryo Kitagawa\textsuperscript{1}, Mitsuya Ishikawa\textsuperscript{2}, Hiroaki Kobayashi\textsuperscript{3}, Toru Nakanishi\textsuperscript{3}, Takao Fukaya\textsuperscript{4}, Yo Watanabe\textsuperscript{5}, Nobuo Yaegashi\textsuperscript{6}

(\textsuperscript{1}Department of Gynecology and Obstetrics, Tohoku Medical and Pharmaceutical University, Japan\textsuperscript{1}, \textsuperscript{2}Department of Gynecologic Cancer, National Cancer Center Hospital, Japan\textsuperscript{2}, \textsuperscript{3}Department of Gynecology and Obstetrics, Kagoshima University, Japan\textsuperscript{3}, \textsuperscript{4}Department of Gynecology and Obstetrics, Tohoku University, Japan\textsuperscript{4})

\begin{tabular}{|l|c|}
\hline
\textbf{Lunchtime Seminar} & November 12 (Sat) 12:10～13:00 \\
\hline & Room 3 (Conference Room 4) \\
\hline
\textbf{Oncofertility} & \\
Fertility Preservation for young female cancer patients-recent topics on ovarian tissue cryopreservation and transplantation. & \\
Nao Suzuki & \\
(\textsuperscript{1}Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan) & \\
Chairperson: Toshiharu Kamura (MCER Foundation, Yanagawa Hospital, Japan) & \\
\hline
\textbf{Session II} & November 12 (Sat) 13:10～14:10 \\
\hline & Room 3 (Conference Room 4) \\
\hline
\textbf{Ovarian Cancer} & \\
Chairpersons: Duk-Soo Bae (Samsung Medical Center, Korea) & \\
Kazunori Ochiai (The Jikei University, Japan) & \\
\hline
\textbf{Peer Review} & \\
Sarikapan Wilailak & \\
(\textsuperscript{1}Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand) & \\
\hline
\textbf{A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203)} & \\
Toyomi Satoh & \\
(\textsuperscript{1}Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan) & \\
\end{tabular}
Endometrial Cancer

Chairpersons: Kung-Liahng Wang (Mackay Memorial Hospital Taitung Branch, Taiwan)
Yasuhiro Udagawa (Professor emeritus, Fujita Health University/Dokkyo Medical College, Japan)

Randomized phase III trial to confirm the survival effect of para-aortic lymphadenectomy for patients with endometrial cancer (JCOG1412)

Hidemichi Watari
(Department of Gynecology, Hokkaido University Hospital, Japan)

Closing Remarks

Hee-Sug Ryu
(Department of Obstetrics & Gynecology, Ajou University Medical Center, Korea)
Kimio Ushijima
(Kurume University Hospital, Japan)
List of Chairpersons

**Session IA**
November 12 (10:00-11:00)
Room 3

Yuen Sheung Hextan Ngan
The University of Hong Kong, China

Hiroyuki Yoshikawa
Ibaraki Prefectural Central Hospital, Japan

**Session IB**
November 12 (11:00-12:00)
Room 3

Uma Devi
Kidwai Memorial Institute of Oncology, India

Daisuke Aoki
Keio University School of Medicine, Japan

**Session II**
November 12 (13:10-14:10)
Room 3

Duk-Soo Bae
Samsung Medical Center, Korea

Kazunori Ochiai
The Jikei University, Japan

**Session III**
November 12 (14:10-15:00)
Room 3

Kung-Liahng Wang
Mackay Memorial Hospital
Taitung Branch, Taiwan

Yasuhiro Udagawa
Professor emeritus, Fujita Health University/Dokkyo Medical College, Japan

**Lunchtime Seminar**
November 12 (12:10-13:00)
Room 3

Toshiharu Kamura
MCER Foundation, Yanagawa Hospital, Japan
Session IA

Cervical Cancer, Early Stage

SIA Peer Review

Yin Nin Chia
Gynaecology & Oncology Specialists, Gleneagles Hospital/National Cancer Center/
KK Women’s and Children’s Hospital, Singapore

CURRICULUM VITAE

Dr Chia Yin Nin is currently a senior consultant gynaecologist and RANZCOG certified gynaecological oncolgist at Gynaecology & Oncology Specialists, Gleneagles Hospital, Singapore. She is also the co-director of the pelvic and peritoneal group and a visiting consultant at the National Cancer Centre, Singapore, as well as a visiting consultant with KK Women’s and Children’s Hospital, Singapore.

Her main area of speciality interest is in the management and treatment of gynaecological cancers namely cancers of the cervix, uterus, ovary, fallopian tubes, vulva and peritoneum; precancer gynaecological diseases; and complex pelvic surgeries including open, laparoscopic and robotic surgeries. She performed the first laparoscopic radical hysterectomy in Singapore in 2011. Her other areas of practice include management of general and benign gynaecological conditions and as well screening and prevention of gynaecological cancers.

She graduated from the National University of Singapore in 1998 with a Bachelor degree in Medicine and Surgery (MBBS). She was awarded the Hoops Medal for Distinction in Obstetrics and Gynaecology and the Singapore Medical Association Bronze medal for excellent academic achievement for the MBBS. In 2002, she obtained her specialist qualification for the Membership to the Royal College of Obstetricians & Gynaecologists, London and in 2008, she obtained her certification in gynaecology oncology from the Royal Australian New Zealand College of Obstetricians & Gynaecologists. She also has a Diploma from Singhealth-Singapore Management University in Healthcare Management Leadership.

Dr Chia Yin Nin was previously the Deputy Head of the Department of Gynaecological Oncology as well as the Head of the Gynaecological Cancer Unit of the Department of Gynaecological Oncology, KKH. Her other past appointments include: KKH Medical Board member, Adjunct Assistant Professor with Duke-NUS Medical School, Singapore and she had received numerous teaching awards for her exemplary teaching at Duke-NUS Medical School.

She is one of the founding member and council member of the Asian Society of Gynaecologic Oncology and she sits on the Editorial Board for the Journal of Gynaecologic Oncology.

Her other academic appointments include President for the Society of Colposcopy and Cytology Singapore and council member of the Gynaecology Oncology subsection of the college of Obstetrics and Gynaecology Singapore.

Dr Chia has keen research interest in the areas of gynaecological cancer and Human Papillomavirus (HPV) vaccines, has participated in key landmark clinical trials in these disease areas, and was previously the Principle Investigator multicentre Bayer Ovarian Cancer 12007 Study.
Nonrandomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2cm or less FIGO stage IB1 uterine cervical cancer (JCOG1101)

Takahide Arimoto¹, Takahiro Kasamatsu²
Department of Obstetrics and Gynecology, The University of Tokyo, Japan¹, Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokuto Hospital, Japan²

The standard surgery for Stage IB1 uterine cervical cancer is radical hysterectomy. The frequency of pathological parametrial invasion is reportedly very low and relapse-free survival is good enough, especially when the tumor diameter is 2 cm or less. However, radical hysterectomy causes loss of desire to void because of damage to the pelvic splanchnic nerve due to surgery. Modified radical hysterectomy has been a standard treatment for minimally invasive cancer of the uterine cervix. Compared with radical hysterectomy, pelvic splanchnic nerves can be preserved in modified radical hysterectomy and it can prevent urination disorder.

Therefore, we conducted a non-randomized confirmatory phase III trial (JCOG1101) in Japan to evaluate the efficacy of modified radical hysterectomy in patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer, for which the current standard is radical hysterectomy. In case that the cancer can be microinvasive, conization is required in order to remove stage IA cases from the study. This study began in January 2013 and a total of 240 patients will be accrued from 44 institutions within 5 years. The primary endpoint is 5-year survival. The secondary endpoints are overall survival, relapse-free survival, local relapse-free survival, percent completion of modified radical hysterectomy, percent local relapse, percent pathological parametrial involvement, days until self-urination and residual urine disappearance, blood loss, operation time, percent post-operative radiation therapy, adverse events and severe adverse events.
Takahide Arimoto

EDUCATION
1992-1998 MD, Faculty of Medicine, The University of Tokyo
2001-2005 PhD in Gynecologic Oncology
Graduate School of Medicine, The University of Tokyo

PROFESSIONAL POSITION AND APPOINTMENTS
1998-1999 Resident in Obstetrics and Gynecology, The University of Tokyo Hospital
1999-2000 Resident in Obstetrics and Gynecology, Sanraku Hospital
2000-2001 Staff Physician of Obstetrics and Gynecology, Fujieda Municipal General Hospital
2001-2004 Physician in The University of Tokyo Hospital
2004-2005 Staff Physician of Obstetrics and Gynecology, Showa General Hospital
2005-2006 Instructor of Obstetrics and Gynecology, The University of Tokyo Hospital
2006-2008 Staff Physician of Gynecology, Saitama Cancer Center
2008-2008 Physician-in-Chief of Gynecology, Saitama Cancer Center
2008-2013 Instructor of Obstetrics and Gynecology, The University of Tokyo Hospital
2013-present Assistant Professor of Obstetrics and Gynecology, The University of Tokyo Hospital

HOSPITAL/UNIVERSITY COMMITTEE APPOINTMENTS
2013-2015 Department Manager of Obstetrics and Gynecology, The University of Tokyo Hospital
2015-present Ward Director of Gynecology, The University of Tokyo Hospital

Takahiro Kasamatsu

Education:
1982 M.D. University of Tsukuba, School of Medicine
1989 Ph.D. (Dr. of Medical Science), University of Tokyo

Professional Training and Employment:
1982-1990 Medical Staff in Department of Gynecology and Obstetrics, University of Tokyo
1990-1993 Director, Department of Gynecology, Tokyo Metropolitan Geriatric Hospital
1993-1998 Medical Staff in Department of Gynecology, Saitama Cancer Center Hospital
1998-2014 Director, Department of Gynecology, National Cancer Center Hospital
2014 Director, Department of Gynecology and Obstetrics, Tokyo Metropolitan Bokutoh Hospital

Societies:
Japanese Society of Gynecology and Obstetrics
Japanese Society of Gynecologic Oncology
Japanese Society of Gynecological and Obstetrical Surgery
Japanese Society of Clinical Oncology
Japanese Cancer Association
Japanese Society of Clinical Cytology
Japanese Society of Gynecologic Pathology
Japan Clinical Oncology Group
International Gynecologic Cancer Society
European Society of Gynaecological Oncology
International Academy of Cytology
Session IB

Cervical Cancer, Late Stage

SIB Peer Review

Chunling Chen
Professor of Obstetrics and Gynecology
Beijing Jadecare Medical Hospital, Beijing, China

CURRICULUM VITAE

Research Areas:
1. Epigenetic Regulation In Gynecological Cancer
Study the abnormal imprinting, LOI, in gynecological cancer and the association and mechanism of DNA methylation and methyltransferases;
2. Cervical cancer transformation
(I) Study the role of Notch passway and HPV in cervical epithelial cells transformation and microRNA expression and regulation in cervical cancer;
3. Psychosocial investigation and intervention in gynecological cancer patients

Clinical Area:
Gynecologic oncologist, laparoscopic surgery in cervical and endometrial cancer patients.

Education:
1984.7-1990.7 Medical School of Peking University, MD
1998.7-2001.7 University of Hong Kong, PhD

Positions and Appointments:

Academic and Hospital Appointments:
1990.7-1995.7. Resident, Dept of Obs&Gyn, First Hospital, Peking University, Beijing, China
1995.7-1996.7. Chief resident, Dept of Obs&Gyn, First Hospital, Peking University, Beijing, China
1996.7-1997.9 Attending Doctor, Dept of Obs&Gyn, First Hospital, Peking University, Beijing, China
1997.9-1998.2 Registered Doctor and IVy Wu Fellow in Dept of Obs & Gye, Queen Mary Hospital, University of Hong Kong.
2001.4-2001.10. Registered Doctor (Hong Kong Medical Council), Queen Mary Hospital, University of Hong Kong.
2001.10-2003.12. Attending Doctor, Department of Obs&Gyn, First Hospital of Peking University, Beijing, China.
2003.8-2003.11. Visiting Scholar of Obs & Gyn, JR Hospital, Oxford University, UK.
2004.1-2006.5. Associate Professor, Department of Obs&Gyn, First Hospital of Peking University, China.
2006.6-2009. Associate Director, Obs&Gyn, Second Hospital, Tsinghua University, Beijing
2006.9-2006.12 Visiting Scholar and Registered Doctor in Tumor Hospital, Regina Elena, Rome, Italy.
2009.4-2010.12 Professor and Executive director of Obs & Gyn, Second Hospital, Tsinghua University, Beijing
2010.12-2014.4 Professor of Obs&Gyn, Vice President, Beijing Royal Integrative Medicine Hospital, Beijing, China.
2014.4-2015.9 Professor of Obs&Gyn, Vice President, Beijing Henghe Hospital, Beijing, China
2015.10-now Professor of Obstetrics and Gynecology, President of Beijing Jadecare Medical Hospital.

Research Appointments:
2004-2006 Associate Professor, Postgraduate Tutor, Department of Obs & Gyn, First Hospital of Peking University, China.
2006-2010 Associate Professor, Postgraduate Tutor, Department of Obs & Gyn, Tsinghua University
2011-Now Professor, Postgraduate Tutor, Department of Obs & Gyn, Beijing University of Chinese Medicine

Training
1997.9-1998.2 Registered doctor in Queen Mary Hospital, Dept of Obs&Gyn
2001.4-2001.10 Registered doctor in Queen Mary Hospital, Dept of Obs&Gyn
2003.8-2003.11 Visiting Scholar of Obs&Gyn, JR Hospital, Oxford University, UK,
2006.8-2006.12 Gynecologic oncologists in Italy (Rome), National Cancer Institute, Regine Elena, IFO Hospital.
2013.4-2013.6 Observer, MD Anderson Cancer Center, USA, Dept of Gynecology
2013.7.1-20 Observer, Memorial Sloan-Kettering Hospital, Dept of Gynecology, NY, USA
2013.7-2013.9 Harvard Medical School and Mass General Hospital in Hospital Administration.

Honors and Awards:
1. Excellent Teacher (1996, 2003), awarded by Peking University First Hospital;
2. Excellent researcher (2000), awarded by Department of Obstetrics and Gynecology, University of Hong Kong;
3. Young investigator award (2001), awarded on Hong Kong International Cancer Congress for oral presentation of “Tumor Growth Inhibition by Antisense Methyltransferase-1 Oligonucleotide in Cervical Cancer”.
4. Young investigator award, First Prize (2002) awarded by Chinese Medical Association, in 2nd international obstetrics and gynecology conference;
Conventional Versus Dose-Dense Paclitaxel in the Combination with Carboplatin in Metastatic or Recurrent Cervical Cancer (JCOG1311)

Ryo Kitagawa\textsuperscript{1}, Mitsuya Ishikawa\textsuperscript{2}, Hiroaki Kobayashi\textsuperscript{3}, Toru Nakanishi\textsuperscript{4}, Takao Fukaya\textsuperscript{1}, Yo Watanabe\textsuperscript{1}, Nobuo Yaegashi\textsuperscript{5}

Department of Gynecology and Obstetrics, Tohoku Medical and Pharmaceutical University, Japan\textsuperscript{1}. Department of Gynecologic Cancer, National Cancer Center Hospital, Japan\textsuperscript{2}. Department of Gynecology and Obstetrics, Kagoshima University, Japan\textsuperscript{3}. Department of Gynecology and Obstetrics, Tohoku University, Japan\textsuperscript{4}

In metastatic or recurrent cervical cancer, cisplatin-based chemotherapy has been standard. In the JCOG0505, we evaluated the clinical benefits of carboplatin-based regimen in cervical cancer for the first time. In detail, conventional paclitaxel plus carboplatin (cTC: paclitaxel 175 mg/m\textsuperscript{2} over 3 hours and carboplatin area under curve 5 mg/mL/min on day 1, repeated every 3 weeks) was compared with paclitaxel plus cisplatin (TP: paclitaxel 135 mg/m\textsuperscript{2} over 24 hours on day 1 and cisplatin 50 mg/m\textsuperscript{2} on day 2, repeated every 3 weeks) as the then global standard regimen. As a result, we verified the significant noninferiority of cTC to TP, and concluded that cTC is a standard treatment option for metastatic or recurrent cervical cancer. Continuously, a randomized controlled trial (JCOG1311) has been started in Japan to compare cTC with dose-dense paclitaxel plus carboplatin (ddTC: paclitaxel 80 mg/m\textsuperscript{2} over 1 hours on day 1, 8, 15 and carboplatin area under curve 5 mg/mL/min on day 1, repeated every 3 weeks). This trial was designed to evaluate the superiority of dose-dense administration of paclitaxel to conventional administration for cervical cancer as same as ovarian cancer, breast cancer, and lung cancer. The primary endpoint is overall survival. Moreover, the addition of bevacizumab, antiangiogenic-directed agent, to cytotoxic chemotherapy has recently shown a promising survival benefit in cervical cancer. Therefore, we are planning to revise JCOG1311 which has adding option of bevacizumab to the protocol treatments.

CURRICULUM VITAE

1995.3 graduated Kyushu University
1995.4 Kyushu University, department of Gynecology and Obstetrics
2001.6 National Cancer Center Hospital, department of Medical Oncology
2003.6 Shizuoka Cancer Center Hospital, department of Medical Oncology
2004.6 Kurume University, department of Gynecology and Obstetrics
2008.4 NTT Medical Center, Tokyo, department of Gynecology and Obstetrics
2016.4 Tohoku Medical and Pharmaceutical University, department of Gynecology and Obstetrics
Lunchtime Seminar

**LS**

Fertility Preservation for young female cancer patients-recent topics on ovarian tissue cryopreservation and transplantation.

**Nao Suzuki**

Department of Obstetrics and Gynecology,
St. Marianna University School of Medicine, Kanagawa, Japan

In young female patients, cancer treatment can cause gonadal dysfunction, loss of fertility, and premature menopause. Cryopreservation of gametes and/or embryos and displacement or shielding of the ovaries during radiation therapy is standard methods for preserving the fertility of young female cancer patients. In 2004, Donnez et al. reported the first live birth after ovarian tissue cryopreservation and transplantation. Subsequently, ovarian tissue cryopreservation and transplantation have been applied clinically as a new approach to fertility preservation, and a new field named Oncofertility has been established in Europe and the United States. It is 12 years since the first live birth was reported after ovarian tissue cryopreservation and transplantation, and this technique has now become an option that should be offered to all young female cancer patients. Ovarian tissue cryopreservation makes it possible to preserve a larger number of primordial follicles. In addition, transplanted ovarian tissue can secrete estrogen. Therefore, this technique may not only preserves fertility, but may also improve symptoms of ovarian failure, prevent cardiovascular disorders related to estrogen deficiency, and lessen the decline of bone density. Currently, slow freezing is the standard method of ovarian tissue cryopreservation, while vitrification is commonly used for cryopreservation of embryos, blastocysts, oocytes, and semen. In recent years, attention has focused on use of vitrification for preservation of ovarian tissue. However, further research is needed to develop the optimum method of ovarian tissue cryopreservation and transplantation. In this session I will give a talk about recent topics related to ovarian tissue cryopreservation and transplantation.

**CURRICULUM VITAE**

**EDUCATION**

1981-1983 Keio High School, Kanagawa, Japan, *cum laude*
1984-1990 M.D., School of Medicine, Keio University, Tokyo, Japan
1993-1997 Ph.D. in Obstetrics and Gynecology, Graduate School of Medicine, Keio University, Tokyo, Japan: Professor Shiro Nozawa)

**MEDICAL LICENSE**

Apr 1990 Passed national medical board examination and licensed to practice medicine in Japan

**POST-GRADUATE MEDICAL TRAINING IN OBSTETRICS AND GYNECOLOGY**

1990-1991 Keio University Hospital, Tokyo, Japan
1991-1992 Saiseikai Utsunomiya Hospital, Tochigi, Japan
1992-1993 Tokyo Dental College General Hospital, Chiba, Japan

POST-GRADUATE RESEARCH TRAINING
Apr 1996-Sep 1999 Visiting Post-Doctoral Research Fellow,
The Burnham Institute: La Jolla, California, U.S.A.
Supervisor: Michiko N. Fukuda, PhD

EXPERIENCE IN OBSTETRICS AND GYNECOLOGY
2000-2005 Instructor at Keio University, School of Medicine, Tokyo, Japan
2005-2008 Assistant Professor at St. Marianna University School of Medicine, Kanagawa, Japan
2009-2010 Associate Professor at St. Marianna University School of Medicine, Kanagawa, Japan
2011-2012 Professor at St. Marianna University School of Medicine, Kanagawa, Japan
2012-present Professor and Chairman at St. Marianna University School of Medicine, Kanagawa, Japan

PROFESSIONAL MEMBERSHIP
Japan Society of Obstetrics and Gynecology: Councilor
Japan Society of Gynecologic Oncology: Board Member
Japanese Gynecologic Oncology Group: Board Member
Japanese Society for Palliative Medicine: Councilor
Japan Society of Fertilization and Implantation: Board Member
Japan Society for Fertility Preservation: President
International Society for Fertility Preservation (ISFP): Board Member
Asian Society for Fertility Preservation (ASFP): President
Session II

Ovarian Cancer

SII Peer Review

Sarikapan Wilailak
Deputy Dean for Academic Affairs and Culture, Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

CURRICULUM VITAE

Biography
Dr. Sarikapan Wilailak is the Professor, Department of Obstetrics and Gynecology, and currently Deputy Dean for Academic Affairs and Culture, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, President of the Thai Gynecologic Cancer Society, Secretary General of the Royal College of Obstetricians and Gynecologists of Thailand.

She earned a medical degree from Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand and received a Thai Board Diploma of Obstetrics and Gynecology and Sub-Board Diploma of Gynecologic Oncology in 1995. In addition, she was a Visiting Fellow in Gynecologic Oncology at Johns Hopkins Hospital in Maryland, Memorial-Sloan-Kettering Cancer Center in New York and M.D.Anderson Cancer Center in Texas, U.S.A. She is a member of many professional societies both domestic and international i.e. Medical Council of Thailand, Royal College of Obstetricians and Gynecologists of Thailand, International Gynecologic Cancer Society, Asian Gynecologic Oncology Group, Asian Society of Gynecologic Oncology, the European Society of Gynaecological Oncology etc. and, at the same time, she is also a leading author of numerous publications and books in the field of Gynecologic Oncology.
A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203)

Toyomi Satoh
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

According to several guidelines for fertility-sparing surgery (FSS) in epithelial ovarian cancer before 2010, the patients with stage IA and grade 1/grade 2 (G1/G2) were selectable for FSS according to the general consensus. The indications for those with stage IC without contralateral ovarian lesions and G1/G2 were controversial. And the indications for those with grade 3 or clear cell carcinoma (CCC) were not suitable for FSS. "Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection" as retrospective investigation was published in JCO in 2010. This report proposed that FSS be considered for stage IA patients with CCC and for stage IC patients with unilateral ovarian involvement and G1/G2, under the conditions of performing complete staging surgery and adjuvant chemotherapy.

In order to expand an indication of fertility-sparing treatment, we have started a prospective non-randomized confirmatory trial for stage IA CCC and stage IC unilateral non-CCC grade 1/grade 2 (G1/G2). The protocol-defined FSS is optimal staging laparotomy including unilateral salpingo-oophorectomy, omentectomy, peritoneal cytology, and pelvic and para-aortic lymph node dissection or biopsy. After FSS, 4-6 cycles of adjuvant chemotherapy with paclitaxel and carboplatin are administered. We plan to enroll 250 patients with an indication of FSS, and then the primary analysis is to be conducted for 63 operated patients with pathologically confirmed stage IA CCC and stage IC unilateral non-CCC G1/G2. The primary endpoint is 5-year overall survival. Secondary endpoints are other survival endpoints and factors related to reproduction.

CURRICULUM VITAE

Residentship
1989-1996 Department of Obstetrics and Gynecology, University of Tsukuba Hospital, Japan

Professional Training and Employment:
1996-2002 Director of Department of Obstetrics and Gynecology, Ibaraki Seinan Medical Center Hospital
2002-2011 Assistant Professor of Department of Obstetrics and Gynecology, University of Tsukuba
2011-2015 Associate Professor of Department of Obstetrics and Gynecology, University of Tsukuba
2015- Professor of Department of Obstetrics and Gynecology, University of Tsukuba
Professional Organizations/Memberships

Editorial Board member
The Journal of Obstetrics and Gynaecology Research (Associate Editor)

Society membership:
Japanese Society of Gynecology and Obstetrics
Japanese Society of Gynecologic Oncology
Japanese Society of Gynecological and Obstetrical Surgery
Japanese Cancer Association
Japanese Society of Clinical Cytology
Japan Clinical Oncology Group
International Gynecologic Cancer Society
Session III  

Peer Review

Efrén Domingo  
University of the Philippines College of Medicine, Philippine General Hospital, Philippines

CURRICULUM VITAE

Educational Background
College, University of the Philippines, Diliman, BS Zoology, Cum Laude, 1978  
Medical Degree, University of the Philippines, College of Medicine, Class of 1982  
Residency in Obstetrics and Gynecology, UP-PGH Medical Center, 1984-1987  
Chief Residency in Obstetrics and Gynecology, UP-PGH Medical Center, 1988  
Fellowship in Gynecologic Oncology, UP-PGH Medical Center, 1989-1990  
Doctor of Philosophy in Hormone Receptor Studies in Endometrial Cancer, Kyoto Prefectural University, Kyoto and Kobe, Japan, 1991-1995

Specialty Certification
Fellow, Philippine Obstetrical and Gynecological Society (POGS)  
Fellow, Society of Gynecologic Oncologists of the Philippines (SGOP)  
Fellow, Philippine College of Surgeons (PCS)  
Fellow, Philippine Society of Oncologists (PSO)  
Fellow, Philippine Society of Cervical Pathology and Colposcopy (PSCPC)  
Fellow, International Gynecologic Cancer Society (IGCS)  
Fellow, European Society of Gynecologic Oncology (ESGO)  
Fellow, Asia Oceania (research organization on) Genital Infection and Neoplasia (AOGIN)

Present Academic Positions
Chairman, Department of Obstetrics and Gynecology, Philippine General Hospital  
Professor 12, Obstetrics and Gynecology and Gynecologic Oncology, University of the Philippines, College of Medicine-Philippine General Hospital

Past Academic Positions
Chairman, Department of Obstetrics and Gynecology, St. Luke’s Medical Center, Global City. (2013-2015)  
Vice Chairman for Academic Affairs, Department of Obstetrics and Gynecology, Makati Medical Center, (2007 to 2012).  
Chief, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Philippine General Hospital (2003-2012)
**Academic Award of Distinction**
Gawad Chancellor Award-Outstanding Academician (1996)
Mamerta Andaya Professorial Chair Recipient (2001-2004)
Centennial Professorial Chair Award (2009)

**Research Awards Received**
Outstanding Researcher in Cancer (2005)
International Publication Award (2008)
Dr. Gloria T. Aragon Award for the Most Outstanding Faculty in Research (2010)
Dr. Rosario Gutierrez Annual Research Grant for Faculty Members (2010)
Finalist, Jose Rizal Memorial Award for Research (2010)
Gawad Chancellor Award for Outstanding Researcher (2011)
Poster Presentation Winner, AOGIN 2011
Academic Excellence for Research, Manila Doctors Hospital (2013)
Honoria Acosta-Sison Memorial Award for Excellence in Research in Obstetrics and Gynecology (2012)
Most Outstanding Alumnus in Research-UPMAS (2014)

**Vital Role in Research Organization and Research Positions Currently Held**
1. President, The Asia Oceania (Research Organization in) Genital Infection and Neoplasia, (AOGIN) 2016-present
2. Member of the Educational Committee, International Gynecological Cancer Society (IGCS), 2002 to present
3. Adviser, International Advisory Board, Glaxo Smith Kline, Bivalent Human Papilloma Virus Vaccine, Asia Pacific, 2005 to present
4. Adviser, CASPRIA Advisory Board, Merck Sharp and Dome, 2006-present

**Positions Held in Specialty Societies**
1. Member, Board of Trustees, Philippine Obstetrical and Gynecological Society (POGS), 2009-2011
2. Board Member, The Asian Society of Gynecologic Oncology (ASGO), 2008 to present
3. Board Member, Philippine Society of Cervical Pathology and Colposcopy (PSCPC), 2006-present
5. Chairman, Philippine Board of Obstetrics and Gynecology, 2015
6. Secretary, Philippine Board of Obstetrics and Gynecology, 2006-2008
7. Member, Philippine Board of Obstetrics and Gynecology, 2013-2014
8. Member, Board of Directors, Society of Gynecologic Oncologists of the Philippines, 1991-2004
9. Secretary, Philippine Society of Oncology, 1991-1993
Randomized phase III trial to confirm the survival effect of para-aortic lymphadenectomy for patients with endometrial cancer (JCOG1412)

Hidemichi Watari
Department of Gynecology, Hokkaido University Hospital, Japan

Background: Two randomized phase III trials from Europe failed to show survival benefit of lymphadenectomy for endometrial cancer. SEPAL study from Japan has shown survival effect of para-aortic lymphadenectomy (PALX) for endometrial cancer with intermediate/high risk for recurrence. However, because of its retrospective fashion, we are preparing a new protocol to conduct a randomized phase III trial to confirm survival effect of PALX for endometrial cancer as a Japan Clinical Oncology Group (JCOG) study 1412.

Study design: Eligible patients include preoperative endometrial cancers except those with potential low-risk for recurrence (FIGO stage IA, grade1/2), stage IIIC2, and stage IVB based on preoperative assessments including imagings and pathologic examination. Some patients with preoperative stage IIIC1 are eligible. Eligible patients who gave their informed consent will be randomly assigned to pelvic lymphadenectomy (PLX) group (control arm) or PLX+PALX group (experimental arm) to show superiority of experimental arm. We evaluate the surgical quality, which should have great influence on the study results, by lymph nodes count, and submitted photos of surgical area. After surgery, patients with postoperative intermediate/high risk for recurrence receive adjuvant chemotherapy (TC), and will be followed-up until recurrence without any treatments. Primary endpoint is overall survival. Secondary endpoints are progression-free survival, recurrence sites, parameters representing surgical invasiveness, and the incidence of adverse events related to surgery and chemotherapy. We also plan to establish a preoperative risk assessment model to predict lymph node metastasis using our data set. Target accrual is 800 patients from 44 institutions of gynecologic cancer study group of JCOG.

CURRICULUM VITAE

Education
1989.3 Graduate from Hokkaido University School of Medicine (MD)
1995.3 Graduate from Hokkaido University Graduate School of Medicine (PhD)

Professional experience
1996.10-2000.3 Postdoctoral fellow, Center for Research on Reproduction and Women’s Health, University of Pennsylvania
2001.11 Assistant Professor, Department of Gynecology, Hokkaido University Hospital
2006.4 Lecturer, Department of Gynecology, Hokkaido University Hospital
2015.10 Associate Professor, Department of Gynecology, Hokkaido University Hospital

Clinical trial group
Japan Clinical Oncology Group (JCOG)
Japanese Gynecologic Oncology Group (JGOG)
NRG Oncology Japan